January 1990 in “Irish Journal of Medical Science (1971 -)” Retinoids are important for treating skin conditions but should be used with caution due to serious side effects and risks during pregnancy.
28 citations
,
August 1981 in “Journal of the American Academy of Dermatology” Retinoic acid is effective for treating eruptive vellus hair cysts.
10 citations
,
August 1998 in “Journal of Investigative Dermatology” 6 citations
,
June 1986 in “The Journal of Dermatology” Reticular erythematous mucinosis syndrome can occur with minimal mucin deposition.
15 citations
,
July 1993 in “The journal of investigative dermatology/Journal of investigative dermatology” Retinoids can change the hair growth cycle by extending the growth phase and shortening the rest phase.
October 1940 in “Clinical and Experimental Optometry” Vitamin A deficiency can cause eye problems and other health issues.
17 citations
,
November 2013 in “Clinical and experimental dermatology” Acitretin therapy may cause hair to repigment and curl.
55 citations
,
July 2016 in “Eye”
October 2023 in “Indian Dermatology Online Journal” Schimmelpenning Syndrome requires careful evaluation and tailored treatment for skin, eye, and developmental issues.
30 citations
,
May 2019 in “Journal of the European Academy of Dermatology and Venereology” Retinoids can help reduce keratin buildup in skin conditions.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
August 2018 in “Journal of The American Academy of Dermatology” A 5-year-old girl with a rare skin disorder was effectively treated with skin creams instead of oral medication.
6 citations
,
September 2014 in “Cutaneous and ocular toxicology” Acitretin can cause eyebrow and eyelash hair loss.
A woman had eye pain and vision loss after a hair growth treatment, but her symptoms improved after a month.
May 2024 in “Rossijskaâ oftalʹmologiâ onlajn” Early treatment with corticosteroids improved her eye condition significantly.
November 2024 in “Medicina” Recognizing scalp symptoms in PRP is crucial for proper diagnosis and treatment.
September 2025 in “Case Reports in Ophthalmology” Short-term use of topical minoxidil can cause eye issues, but stopping it can resolve the problem.
9 citations
,
August 2002 in “British journal of ophthalmology” The document reports a rare case of ECCL with a new association with optic disc colobomas.
June 2023 in “University of Thi-Qar Journal of Science” Retinoids effectively treat skin aging but have safety and stability issues.
July 2020 in “Nepalese journal of ophthalmology” A boy with progeria had eye problems and signs of aging like hair loss and skin wrinkling.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
December 2020 in “American Journal of Transplantation” Early recognition and treatment of VATS in transplant patients improve outcomes.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib provides new treatment options for diverse alopecia areata patients.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
July 2023 in “Media Dermato Venereologica Indonesiana” Accurate diagnosis of RDEB-mitis in older adults is crucial for proper management without immunosuppressants.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
January 1987 in “Toxicological sciences” SMR-2 and SMR-6 are much more toxic than retinoic acid, causing severe symptoms and organ damage in mice.
36 citations
,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.